阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌的疗效及预后因素分析

发布时间：2018-03-31 04:35

  本文选题：阿比特龙　切入点：未经化疗　出处：《上海交通大学学报(医学版)》2017年11期

【摘要】：目的·评价阿比特龙(AA)联合泼尼松治疗转移性去势抵抗性前列腺癌(mCRPC)患者的疗效,并分析预后因素。方法·回顾性分析2012年9月—2016年12月上海交通大学医学院附属仁济医院诊治的112例mCRPC患者的临床资料,其中42例先前接受过化疗,70例先前未接受过化疗。观察终点为前列腺特异性抗原无进展生存期(PSA PFS)、影像学无进展生存期(r PFS)以及总生存期(OS)。采用Cox单因素和多因素分析对患者PSA PFS、rPFS以及OS相关的预后因素进行分析。结果·中位随访时间20.2个月,59例患者死亡。中位PSA PFS 8.9(7.8~10.0)个月,中位rPFS 9.7(9.0~10.4)个月,中位OS 22.2(20.3~24.1)个月。多因素分析中,先前是否接受化疗、粒淋比(≥3 vs3)、血清乳酸脱氢酶水平(≥196 U/L vs196 U/L)、先前内分泌治疗有效时间(12个月vs≥12个月)、ECOG评分(≤1 vs 2)与mCRPC患者接受AA联合泼尼松治疗的PSA PFS与rPFS显著相关,先前是否接受化疗、ECOG PS(≤1 vs 2)与OS显著相关。结论·AA联合泼尼松治疗中国mCRPC患者取得较好疗效,先前是否接受化疗、ECOG PS(≤1 vs 2)与接受AA治疗的mCRPC患者OS显著相关。
[Abstract]:Objective to evaluate the efficacy and prognostic factors of Abiproterol combined with prednisone in the treatment of metastatic ovariectomized prostate cancer (mCRPC).Methods the clinical data of 112 patients with mCRPC treated in Renji Hospital affiliated to Shanghai Jiaotong University Medical College from September 2012 to December 2016 were retrospectively analyzed.The end points were PSA PFSV, r PFSand total survival time (PSAs) and total survival time (TFS).The prognostic factors associated with PSA PFSR rPFS and OS were analyzed by Cox single factor and multivariate analysis.Results the median follow-up time was 20.2 months and 59 patients died.The median PSA PFS was 8. 9 / 7 / 10. 0) months, the median rPFS was 9. 7 / 9 / 10.4) months, and the median OS was 22. 2 / 20. 3 / 24. 1) months.In multivariate analysis, whether previously received chemotherapy,The ratio of granulocyte to lymphocyte (鈮，

本文编号：1689199